We describe a case of refractory RP in which work-up revealed TRAPS as the etiology, with a significant clinical response upon switching from canakinumab (a human monoclonal immunoglobulin G1 antibody against IL-1β) to rilonacept (an IL-1α and IL-1β cytokine trap). Here, IL1A is linked to TNF receptor 1-associated periodic fever syndrome.